Home Sleep Test (HST)

Watermark Medical's ARES™ 620 is a smaller, digital, and more advanced version of in-home sleep apnea testing solutions. It records respiratory events and offers multiple-channel recording, including airflow, SpO2, EEG, EOG, EMG, heart rate, head position, head movement, and snoring. With the remote send feature, up to 3 nights of data can be sent from the device, reducing the time to diagnosis. The device measures hypoxemia, cardiac parameters, neurological/behavioral aspects, and arousal indicators. Watermark Medical invites you to explore the innovative features of ARES™ 620.

It is extremely important to identify and diagnose sleep disorders, especially Obstructive Sleep Apnea (OSA), by using Home Sleep Testing (HST) for the sake of both physical and mental well-being. If left untreated, sleep disorders can lead to various health issues such as cardiovascular problems, metabolic disorders, and compromised immune function. By accurately detecting sleep disturbances through HST, timely intervention can be provided, and targeted treatment can be given, thus reducing the risk of physical health complications. It is equally important to consider the impact of sleep disorders on mental health, as they can lead to cognitive impairment, mood disturbances, and increased stress levels. By identifying and addressing sleep disorders through HST and managing conditions like OSA, individuals can experience better sleep quality, improved cognitive function, and an overall better quality of life, promoting physical and mental well-being.

OSA was Found in Over 70% of Type 2 Diabetics in a Meta-Analysis, Therefore Clinicians Should Consider Treatments for Patients.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449487

Scientific literature spanning several years has consistently highlighted the associations between Obstructive Sleep Apnea (OSA) and a myriad of diseases, including but not limited to glaucoma, end-stage renal disease, chronic obstructive pulmonary disease, polycystic ovarian syndrome, metabolic syndrome, cardiovascular disease, stroke, depression, obesity, and diabetes mellitus (DM). Notably, OSA can affect both obese and non-obese individuals, as well as children with enlarged tonsils and adenoids. The literature suggests that treating OSA can improve the underlying conditions, as evidenced by studies indicating enhanced ejection fraction, reduced carotid intimal thickening, coronary artery disease benefits, sinus rhythm post-cardioversion maintenance, and improved insulin resistance. It is emphasized that early diagnosis and treatment of OSA play a pivotal role in preventing the heightened morbidity and mortality associated with these conditions, while untreated OSA is linked to an increased risk of death.

Early Diagnosis and Treatment of OSA can Significantly Reduce Morbidity and Mortality Risks